SynthesisBMC nephrology2025
Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes.Cells · 2026Review
- Integrated single cell multiomic profiling and functional validation reveal distinct cellular routes to human plasma cell differentiation.bioRxiv : the preprint server for biology · 2026Article
- Gut microbiota dysbiosis and immune responses: insights from IgA nephropathy and inflammatory bowel disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Dysregulation of cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) signaling pathway is associated with multiple core pathogenesis of IgAN patients and the elevation levels of serum BAFF and APRIL are positively correlated with the severity of the disease in IgAN patients. This study aimed to comprehensively evaluate the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients.
methodsLiterature search was performed using PubMed, Embase, Web of Science, Scopus and Cochrane Library from inception to 28 February 2025. All randomized controlled trials (RCTs) were identified. Data analysis was conducted using RevMan 5.4.
resultsThree Phase Ⅱ double-blind RCTs involving 263 primary IgAN patients were included. Compared with the control treatment, BAFF/APRIL dual antagonists achieved a greater percentage decrease from baseline in urine protein-to-creatinine ratio (UPCR) [mean difference (MD) -36.67, 95% confidence interval (CI) -40.31 to -33.03] and circulating galactose-deficient IgA1 (Gd-IgA1) (MD -45.55, 95% CI -61.33 to -29.78), while led to a greater increase from baseline in estimated glomerular filtration rate (eGFR) (MD 9.65, 95% CI 7.73 to 11.57). However, BAFF/APRIL dual antagonists were associated with a higher risk of injection site reactions [odds ratio (OR) 30.94, 95% CI 6.43 to 148.75] and greater percentage decrease from baseline in serum IgG (MD -22.65, 95% CI -33.83 to -11.48), IgA (MD -41.41, 95% CI -55.35 to -27.48) and IgM (MD -63.39, 95% CI -77.29 to -49.50).
conclusionBased on the currently limited evidence, we cautiously conclude that BAFF/APRIL dual antagonists may reduce the levels of 24-hour UPCR and circulating Gd-IgA1 in patients with IgAN, while concomitantly delay the decline of eGFR. However, it should be noted that BAFF/APRIL may cause injection site reactions. More importantly, BAFF/APRIL dual antagonists may reduce the levels of serum IgG, IgA and IgM, potentially weakening the immune function of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.